Orally efficacious NR2B-selective NMDA receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 4, 2003, Pages 697-700

  Claiborne, Christopher F ^a   McCauley, John A ^a   Libby, Brian E ^a   Curtis, Neil R ^b   Diggle, Helen J ^b   Kulagowski, Janusz J ^b   Michelson, Stuart R ^a   Anderson, Kenneth D ^a   Claremon, David A ^a   Freidinger, Roger M ^a   Bednar, Rodney A ^a   Mosser, Scott D ^a   Gaul, Stanley L ^a   Connolly, Thomas M ^a   Condra, Cindra L ^a   Bednar, Bohumil ^a   Stump, Gary L ^a   Lynch, Joseph J ^a   Macaulay, Alison ^b   Wafford, Keith A ^b   Koblan, Kenneth S ^a   Liverton, Nigel J ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDINE DERIVATIVE; CARRAGEENAN; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG SYNTHESIS; HYPERALGESIA; LOCOMOTION; MOTOR COORDINATION; NONHUMAN; PAIN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 0037293059     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)01061-2     Document Type: Article

References (21)

1. Le D.A., Lipton S.A. Drugs & Aging. 18:2001;717.
2. Max M.B., Byas-Smith M.G., Gracely R.H., Bennet G.J. Clin. Neuropharmacol. 18:1995;360.
3. Muir K.W., Lees K.R. Stroke. 26:1995;503.
4. Sugihara H., Moriyoshi K., Ishii T., Masu M., Nakanishi S. Biochem. Biophys. Res. Commun. 185:1992;826.
5. Cull-Candy S., Brickley S., Farrant M. Curr. Opin. Neurobiol. 11:2001;327.
6. Monyer H., Burnashev N., Laurie D.J., Sakmann B., Seeburg P.H. Neuron. 12:1994;529.
7. Boyce S., Wyatt J.K., Webb R., O'Donnell R., Mason G., Rigby M., Sirinathsinghji D., Hill R.G., Rupniak N.M.J. Neuropharmacology. 38:1999;611.
8. Williams K. Mol. Pharmacol. 44:1993;851.
9. Kew J.N.C., Trube G., Kemp J.A. J. Physiol. 497.3:1996;761.
10. Chizh B.A., Headley P.M., Tzschentke T.M. Trends Pharmacol. Sci. 22:2001;636.
11. (a) Nikam S.S., Meltzer L.T. Curr. Pharm. Des. 8:2002;845.
12. (b) Chenard B.L., Menniti F.S. Curr. Pharm. Des. 5:1999;381.
13. Chenard B.L., Bordner J., Butler T.W., Chambers L.K., Collins M.A., DeCosta D.L., Ducat M.F., Dumont M.L., Fox C.B., Mena E.E., Menniti F.S., Nielsen J., Pagnozzi M.J., Richter K.E.G., Ronau R.T., Shalaby I.A., Stemple J.Z., White W.F. J. Med. Chem. 38:1995;3138.
14. Wright, J. L.; Kesten, S. R.; Upasani, R. B.; Lan, N. C. PCT Int. Appl., WO 2000000197, 2000. Chem. Abstr. 2000, 132, 64255.
15. Pinard E., Alanine A., Bourson A., Buttelmann B., Heitz M.-P., Mutel V., Gill R., Trube G., Wyler R. Bioorg. Med. Chem. Lett. 12:2002;2615.
16. For NR2B Binding and FLIPR assay protcols see: McCauley, J. A.; Theberge, C. R.; Liverton, N. J.; Claremon, D. A.; Claiborne, C. F. US Patent 6,316,474 B1, 2001. Chem. Abstr. 2001, 134, 340508.
17. Curtis, N. R.; Diggle, H. J.; Kulagowski, J. J.; London, C.; Grimwood, S.; Hutson, P. H.; Murray, F.; Richards, P.; Macaulay A.; Wafford, K. A. Bioorg. Med. Chem. Lett. See preceeding communication. doi:10.1016/S0960-894X(02)01060-0.
18. 2O, sonicated for 5 min and filtered. The imidate salt (2.8g, 65% yield) was recovered as a white solid.
19. Dox A.W. Org. Synth. CV1:1932;5.
20. Priestley T., Laughton P., Myers J., Le Bourdellès B., Kerby J., Whiting P.J. Mol. Pharmacol. 48:1995;841.
21. 2 (0.5); pH 7.25. Agonists and antagonist were applied locally by fast perfusion from a double-barreled pipette and experiments were performed at room temperature. Inhibition curves for NMDA antagonists were obtained in the presence of 10μM glutamate and 1 μM glycine (10 μM for NR1a/NR2A). Increasing concentrations of antagonist was pre-applied for 30 s followed by two co-applications of glu/gly for 5 s. Inhibition of the second glu/gly response in the presence of antagonist was determined.